Verbet

# Verbet ## Overview - **Classification**: Selective Serotonin (5-HT3) Receptor Antagonist - **Mechanism**: Blocks serotonin's action on 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and afferent vagal nerve endings in the GI tract, preventing nausea and vomiting. ## Primary Indications 1. **Chemotherapy-Induced Nausea and Vomiting (CINV)** - Prevention of acute and delayed CINV. 2. **Postoperative Nausea and Vomiting (PONV)** - Prevention and treatment of PONV. 3. **Radiation-Induced Nausea and Vomiting (RINV)** - Prevention of RINV. ## Adult Dosing ### Standard Dosing **Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)** - **Dose**: **8 mg** - **Frequency**: Once, 30 minutes prior to chemotherapy. May repeat **8 mg** PO/IV Q12H for up to 5 days for delayed CINV. - **Route**: Oral (PO) or Intravenous (IV) over 2-5 minutes. - **Maximum Dose**: **16 mg/day** (oral) or **16 mg single dose** (IV). **Prevention/Treatment of Postoperative Nausea and Vomiting (PONV)** - **Dose**: **4 mg** - **Frequency**: Single dose immediately prior to induction of anesthesia, or postoperatively for treatment. - **Route**: Intravenous (IV) over 2-5 minutes. ### Dose Adjustments - **Renal Impairment**: No dose adjustment needed for CrCl >15 mL/min. For CrCl ≤15 mL/min, limit dose to **8 mg/day**. - **Hepatic Impairment**: For severe hepatic impairment (Child-Pugh score ≥10), limit total daily dose to **8 mg**. - **Elderly Patients**: No specific dose adjustment needed. Monitor for QTc prolongation, especially with comorbidities. ## Pediatric Dosing ### Neonates (0-28 days) - **Consideration**: Generally not recommended due to limited data and potential for QTc prolongation. Use only if absolutely necessary for severe, refractory emesis. - **Dose**: **0.05 mg/kg** - **Frequency**: Once, 30 minutes before chemo. Repeat Q24H for max 2 doses total. - **Maximum**: **1 mg/dose**. - **Special Notes**: Closely monitor ECG, heart rate, and electrolytes. Administer slowly over 15-30 minutes. ### Infants (1-12 months) - **Prevention of CINV**: - **Dose**: **0.1 mg/kg** - **Frequency**: Once, 30 minutes before chemotherapy. Max 3 doses in 24 hours. - **Maximum**: **4 mg/dose** (single dose). - **Prevention of PONV**: - **Dose**: **0.1 mg/kg** - **Frequency**: Single dose prior to induction of anesthesia or post-op. - **Maximum**: **4 mg/dose**. ### Children (1-12 years) - **Prevention of CINV**: - **Dose**: **0.15 mg/kg** - **Frequency**: 30 minutes before chemotherapy, then 4 and 8 hours after the initial dose. Max 3 doses per 24 hours. - **Maximum**: **16 mg/dose** (single dose) or **24 mg/day**. - **Prevention of PONV**: - **Dose**: **0.1 mg/kg** - **Frequency**: Single dose prior to induction of anesthesia or post-op. - **Maximum**: **4 mg/dose**. ### Adolescents (13-18 years) - **Dose**: Dosing generally follows adult recommendations. - **Maximum**: **16 mg/day** (oral) or **16 mg single dose** (IV for CINV) / **4 mg single dose** (IV for PONV). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Verbet or other 5-HT3 antagonists. - **Absolute**: Concomitant use with **apomorphine** (risk of profound hypotension and loss of consciousness). - **Relative**: Pre-existing QTc prolongation, uncorrected electrolyte abnormalities (hypokalemia, hypomagnesemia). ### Common Adverse Effects - **Very Common (>10%)**: Headache, Constipation. - **Common (1-10%)**: Dizziness, Fatigue, Diarrhea, Injection site reactions (for IV). - **Serious but Rare**: Serotonin syndrome (especially with other serotonergic drugs), Torsades de Pointes/QTc prolongation (dose-dependent), Hypersensitivity reactions (anaphylaxis, angioedema). ### Key Drug Interactions - **Apomorphine**: **CONTRAINDICATED**. May cause severe hypotension and unconsciousness. - **QT-prolonging drugs** (e.g., amiodarone, quinidine, sotalol, antipsychotics): Increased risk of cardiac arrhythmias. Avoid co-administration if possible. - **Serotonergic drugs** (e.g., SSRIs, SNRIs, MAOIs, TCAs, fentanyl, tramadol): Increased risk of **serotonin syndrome**. Monitor for mental status changes, autonomic instability, and neuromuscular abnormalities. - **Phenytoin, Carbamazepine, Rifampin**: May reduce Verbet plasma levels, potentially decreasing efficacy. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG (if patient has risk factors for QTc prolongation or is on other QT-prolonging drugs), serum electrolytes (potassium, magnesium). - **During Treatment**: Monitor for efficacy and adverse effects. For high-risk patients, repeat ECG and electrolyte monitoring. - **Clinical Signs**: Watch for signs of headache, constipation, dizziness. Immediately report any signs of irregular heartbeat, seizures, or serotonin syndrome (agitation, confusion, fever, muscle rigidity). ## Clinical Pearls - 💡 **Timing is Key**: Administer Verbet **before** the emetogenic event (e.g., chemotherapy, surgery) for optimal efficacy. - 💡 **Constipation Management**: Proactively advise patients on fiber, fluids, or stool softeners to manage common constipation. - 💡 **ECG Caution**: Be aware of the risk of QTc prolongation, especially in patients with cardiac disease, electrolyte imbalances, or on other QT-prolonging medications. Correct electrolyte abnormalities before administering. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.